Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Emicerfont (Primary) ; Paroxetine
- Indications Social phobia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 05 Feb 2008 Status changed from in progress to completed according to Neurocrine media release.
- 24 Nov 2006 New trial record.